Abstract: Methods and systems for diagnosing a condition of a central nervous system are provided. A method includes providing a DBSI-MRI data set obtained from the central nervous system of the subject, and transforming the DBSI-MRI data set to obtain at least one DBSI biomarker value. The method further includes comparing each DBSI biomarker value to at least one corresponding threshold value from a diagnostic database to obtain a relation between each DBSI biomarker value and the at least one corresponding threshold value, and diagnosing the condition according to at least one diagnostic rule, wherein each diagnostic rule defines a candidate condition in terms of the relations between the at least one DBSI biomarker value and the at least one corresponding threshold value.

Abstract: Compositions and methods are provided for modifying diagnosing and treating inflammatory disease. The methods and compositions can be used to ameliorate the effects of a deficiency in the LAP pathway for clearing dead cells. Thus, methods are further provided for modulating dead cell clearance using an effective amount of a pharmaceutical composition that targets the LAP pathway. Accordingly, pharmaceutical compositions that target the LAP pathway re provided herein. The methods and compositions described herein can be used to treat inflammatory disease, such as systemic lupus erythematosus (SLE).

Abstract: A traffic management mechanism can employ a two-tiered approach for managing background traffic based on prioritizing tasks by remaining time flexibility then scheduling prioritized tasks using linear programming.

Abstract: Bio-photonic devices or target cells and cell cultures including bio-photonic devices and target cells are provided. Methods of preparing cell cultures including bio-photonic devices and target cells are also provided. Methods of analyzing the electrophysiology of target cells using the cell cultures are provided. Systems for analyzing the electrophysiology of target cells are also provided.

Abstract: The present disclosure provides compositions comprising 25-hydroxycholesterol, derivatives and prodrugs thereof, and methods of use thereof. Specifically, disclosed herein are methods of decreasing neuronal cell death.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.

Abstract: A method for rapid computation of three-dimensional displacement and Lagrange strain in a high resolution filed of phase data obtained with Displacement Encoding with Stimulated Echoes (DENSE) in magnetic resonance images of the myocardium. The method includes semi-automated segmentation of a region of a heart, phase unwrapping the images in three dimensions, and a custom radial point interpolation method (RPIM). The RPIM is a meshfree numerical analysis method that uses radial basis functions and polynomial functions to calculate the Lagrange strain of DENSE displacement data acquired from the myocardium.

Abstract: Kits, recyclable covalently crosslinked polymer networks and composites, and related methods of making and recycling are described.

Abstract: The present disclosure provides compositions and methods for treating bacterial infections in a subject. The methods comprise administering a compound that binds a FAD-dependent flavoenzyme and a tetracycline, analog, derivative, or pharmaceutically acceptable salt thereof.

Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; and administering an amount of a butyrate compound to the subject based at least partially on the determining step so as to promote Adenosine triphosphate (ATP) production in the subject as well as to methods of screening for compounds that restore cellular mitochondrial activity.

Abstract: A treatment planning system for generating patient-specific treatment. The system including one or more processors programmed to receive a radiation treatment plan (RTP) for irradiating a target over the course of one or more treatment fractions, said RTP including a planned dose distribution to be delivered to the target, receive motion data for at least one of the treatment fractions of the RTP, receive temporal delivery metric data for at least one of the treatment fractions of the RTP, calculate a motion-compensated dose distribution for the target using the motion data and the temporal delivery metric data to adjust the planned dose distribution based on the received motion data and temporal delivery metric data, and compare the motion-compensated dose distribution to the planned dose distribution.

Abstract: A photonic molecule laser is described that includes a photonic molecule waveguide coupled to a photonic molecule seeding source configured to deliver a plurality of photonic molecules. The photonic molecule waveguide includes a second dopant maintained at a population inverted state with an energy level transition corresponding to a second frequency that is an N-fold multiple of a first frequency and amplifies the number of photonic molecules via stimulated emission. The photonic molecule seeding source includes a waveguide with a first dopant maintained at a population inverted state with an energy level transition corresponding to the first frequency. A pump source is coupled to the waveguide configured to deliver a first frequency laser pulse with pulse coherence time less than the photonic molecules correlation time. Each photonic molecule includes a threshold bound state of N first frequency photons, and each photonic molecule has the second frequency.

Abstract: A computing device for use in a system for mapping brain activity of a subject includes a processor. The processor is programmed to select a plurality of measurements of brain activity that is representative of at least one parameter of a brain of the subject during a resting state. Moreover, the processor is programmed to compare at least one data point from each of the measurements with a corresponding data point from a previously acquired data set from at least one other subject. The processor is also programmed to produce at least one map for each of the measurements based on the comparison of the resting state data point and the corresponding previously acquired data point. The processor may also be programmed to categorize the brain activity in a plurality of networks in the brain based on the map.

Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.

Abstract: Systems and methods for virtual reality or augmented reality (VR/AR) visualization of 3D medical images using a VR/AR visualization system are disclosed. The VR/AR visualization system includes a computing device operatively coupled to a VR/AR device, and the VR/AR device includes a holographic display and at least one sensor. The holographic display is configured to display a holographic image to an operator. The computing device is configured to receive at least one stored 3D image of a subject's anatomy and at least one real-time 3D position of at least one surgical instrument. The computing device is further configured to register the at least one real-time 3D position of the at least one surgical instrument to correspond to the at least one 3D image of the subject's anatomy, and to generate the holographic image comprising the at least one real-time position of the at least one surgical instrument overlaid on the at least one 3D image of the subject's anatomy.

Abstract: The present invention is directed towards isolated antibodies that bind to GRP78.

Abstract: The Hybrid Photonic Plasmonic Interconnect (HyPPI) combines both low loss photonic signal propagation and passive routing with ultra-compact plasmonic devices. These optical interconnects therefore uniquely combine fast operational data-bandwidths (in hundreds of Gbps) for light manipulation with low optical attenuation losses by hybridizing low loss photonics with strong light-matter-interaction plasmonics to create, modulate, switch and detect light efficiently at the same time. Initial implementations were considered for on-chip photonic integration, but also promising for free space or fiber-based systems. In general two technical options exist, which distinguished by the method the electric-optic conversion is executed: the extrinsic modulation method consists of an continuous wave source such as an LED or laser operating at steady power output, and signal encoding is done via an electro-optic modulator downstream of the source in the interconnect.

Abstract: The present disclosure provides the use of two very long chain ceramides for determining the risk of cardiovascular disease.